加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
Luis
Supply Chain at Apellis
加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
Learn More
加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
w加速器官网
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
@ApellisPharma
加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
FOR PATIENTS
加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.
加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALS加速器试用3小时-魔法加速器官网-永久不收费的加速器2024-加速器试用3小时
so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike
We challenge conventional thinking and always question if there's a better way.
Join Us
Patricia
Quality Assurance at Apellis
This website is intended for residents of the U.S.